Señales en vivo de KZIA | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (21 may 2024 @ 11:45):

Stats
Volumen de hoy	31 077.00
Volumen promedio	467 487
Capitalización de mercado	6.61M
EPS	$0 ( 2024-03-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.760
ATR14	$0.00700 (2.50%)

Insider Trading

Date	Person	Action	Amount	type
2013-11-04	Austin Josiah T	Sell	25 400	Sponsored ADRs, each convertible into 25 ordinary shares
2013-11-05	Austin Josiah T	Sell	23 922	Sponsored ADRs, each convertible into 25 ordinary shares
2013-10-25	Austin Josiah T	Sell	62 591	Sponsored ADRs, each convertible into 25 ordinary shares
2013-10-28	Austin Josiah T	Sell	37 409	Sponsored ADRs, each convertible into 25 ordinary shares
2013-10-29	Austin Josiah T	Sell	1 100	Sponsored ADRs, each convertible into 25 ordinary shares

INSIDER POWER
0.00
Last 100 transactions
Buy: 5 568 614 \| Sell: 243 947

Volumen Correlación

Largo: -0.51 (weak negative)

Corto: 0.67 (moderate)

Signal:(55.347) Neutral

Kazia Therapeutics Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kazia Therapeutics Correlación - Moneda/Commodity

-0.34
( neutral )

-0.33
( neutral )

0.00
( neutral )

-0.21
( neutral )

0.00
( neutral )

0.37
( neutral )

Kazia Therapeutics Finanzas

Annual	2023
Ingresos:	$555.00
Beneficio Bruto:	$555.00 (100.00 %)
EPS:	$-1.120

FY	2023
Ingresos:	$555.00
Beneficio Bruto:	$555.00 (100.00 %)
EPS:	$-1.120

FY	2022
Ingresos:	$25.00
Beneficio Bruto:	$25.00 (100.00 %)
EPS:	$-1.860

FY	2021
Ingresos:	$15.18M
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.716

Financial Reports:

No articles found.

Kazia Therapeutics Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Kazia Therapeutics

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.